Amit Sachdev - 01 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Patient Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2023
Transactions value $
$0
Form type
4
Filing time
03 Feb 2023, 15:56:38 UTC
Previous filing
11 Mar 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Gift $0 -1.67K -13.14% $0.00 11.1K 17 May 2022 Held in Trust
transaction VRTX Common Stock Award $0 +10.3K +19.35% $0.00 63.7K 01 Feb 2023 Direct F1
transaction VRTX Common Stock Award $0 +8.21K +12.89% $0.00 71.9K 01 Feb 2023 Direct F2
transaction VRTX Common Stock Award $0 +7.87K +10.94% $0.00 79.8K 01 Feb 2023 Direct F3
holding VRTX Common Stock 882 01 Feb 2023 401(k)
holding VRTX Common Stock 8.86K 01 Feb 2023 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.
F3 Restricted stock unit award that vests in installments beginning on 02/10/2024.